Nanoforming Biologics And GLP-1s: From I.V. To Sub Q And Inhaled Delivery

Developing new delivery routes for biological therapies is essential for creating more patient-centric and effective treatments. By using nanoforming techniques, it's possible to simplify dosing regimens and enhance patient comfort, compliance, and even reduce overall healthcare costs.

This is best demonstrated through two real-world examples.

First, a case study on nanoformed Trastuzumab shows how particle size can impact drug product behavior, including viscosity and syringeability. A highly concentrated subcutaneous formulation was created, with stability and quality evaluations showing strong results, suggesting improved patient comfort.

Second, a case study on nanoformed Semaglutide highlights its potential as an inhaled alternative to current formulations. The dry powder was shown to have a high fine particle fraction, which indicates it can be deposited deep into the lungs for systemic absorption, offering a new, non-invasive delivery option.